...A. Highlights: Last year, continued to transform Co. and advance mission to eradicate cancer. 1. 2. Strengthened R&D capabilities in cancer test menu by adding Thrive, Base Genomics, Paradigm and Viomics teams to Co.'s family. 3. Tested more than 4m people across all of its tests and generated nearly $1.5b in total revenue due to team's resilience throughout pandemic. 4. Backed by aforementioned strengths, Co. is confident in long-term growth of Cologuard Oncotype DX in future tests, including minimum residual disease, liquid biopsy and multi-cancer screening tests. 5. Plans to extend leadership throughout cancer continuum addressing largest patient impact opportunities and diagnostics. Cumulatively, this represents a combined total opportunity of $60b. a. 6. People, scientific platform and leading test place Co. at forefront of earlier cancer detection in precision medicine....
